Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
I Karniadakis, N Mazonakis, C Tsioutis… - Infectious Disease …, 2023 - mdpi.com
Vaccines remain the cornerstone of medical prevention and are highly effective in reducing
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …
[HTML][HTML] Determining and comparing the real-world effectiveness of molnupiravir and nirmatrelvir-ritonavir in patients hospitalized with COVID-19
YR Jang, Y Oh, JY Kim - Journal of Korean Medical Science, 2024 - ncbi.nlm.nih.gov
Background Current guidelines recommend using nirmatrelvir-ritonavir for coronavirus
disease 2019 (COVID-19) treatment, but its potential drug interactions and contraindications …
disease 2019 (COVID-19) treatment, but its potential drug interactions and contraindications …
[HTML][HTML] Current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients
DV Parums - … science monitor: international medical journal of …, 2022 - ncbi.nlm.nih.gov
On 4 th November 2021, the first oral antiviral drug for COVID-19, molnupiravir (Lagevrio®),
received full regulatory approval from the Medicines and Healthcare Products Regulatory …
received full regulatory approval from the Medicines and Healthcare Products Regulatory …
Covid-19: What is the evidence for the antiviral molnupiravir?
A Extance - bmj, 2022 - bmj.com
Covid-19: What is the evidence for the antiviral molnupiravir? | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …
[HTML][HTML] Molnupiravir for intra-household prevention of COVID-19: the MOVe-AHEAD randomized, placebo-controlled trial
SA Alpizar, J Accini, DC Anderson, B Eysa… - Journal of Infection, 2023 - Elsevier
Objectives To evaluate the efficacy and safety of molnupiravir for intra-household post-
exposure prophylaxis (PEP) of COVID-19. Methods MOVe-AHEAD was a randomized …
exposure prophylaxis (PEP) of COVID-19. Methods MOVe-AHEAD was a randomized …
Nirmatrelvir/Ritonavir and Molnupiravir: an update on COVID-19 Antivirals in the Omicron era
F Faraz, MEU Rehman, A Shahid… - Expert Review of …, 2023 - Taylor & Francis
Information Classification: General impact on the morbidity and mortality of patients
worldwide. In an effort to address this ongoing public health crisis, researchers and …
worldwide. In an effort to address this ongoing public health crisis, researchers and …
Safety and efficacy of antivirals against SARS-CoV-2
DB Sidebottom, DD Smith, D Gill - bmj, 2021 - bmj.com
In April 2021, the UK government launched an antivirals taskforce with the aim of deploying
oral drugs for the prevention and treatment of covid-19 by this autumn. 1 The ambitious goal …
oral drugs for the prevention and treatment of covid-19 by this autumn. 1 The ambitious goal …
[HTML][HTML] Rebound COVID-19 and cessation of antiviral treatment for SARS-CoV-2 with Paxlovid and molnupiravir
DV Parums - … science monitor: international medical journal of …, 2022 - ncbi.nlm.nih.gov
One of the most recently described clinical associations with SARS-CoV-2 infection is
rebound COVID-19, which occurs between five and eight days following the cessation of …
rebound COVID-19, which occurs between five and eight days following the cessation of …
[PDF][PDF] Molnupiravir for the treatment of COVID-19
BG Santani, BW LeBlanc, RP Thakare - Drugs Today (Barc), 2022 - researchgate.net
Summary Molnupiravir (MK-4482, EIDD-2801) is a promising broad-spectrum experimental
antiviral developed by Merck & Co. It is a nucleoside analogue prodrug that undergoes rapid …
antiviral developed by Merck & Co. It is a nucleoside analogue prodrug that undergoes rapid …